Journal article
Mixed‐Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis
Abstract
The prevalence of mixed hepatitis C virus (HCV) genotype infection in a representative Canadian HCV cohort is reported and virological response with direct acting antiviral (DAA) treatment was evaluated. 3272 HCV-positive participants were enrolled, of which 2945 (90.0%) initiated DAA therapy. 0.8% were identified with mixed genotype infection. Overall sustained virological response (SVR) was 99.1% and did not differ based on mixed genotype …
Authors
Imsirovic H; Macphail G; Conway B; Fraser C; Borgia S; Smyth D; Wong A; Vachon M; Webster D; Liu H
Journal
Journal of Viral Hepatitis, Vol. 31, No. 11, pp. 775–779
Publisher
Wiley
Publication Date
November 2024
DOI
10.1111/jvh.13995
ISSN
1352-0504